Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 7,084 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Radiolabeled (99mTc) GP (Glycopeptide); Radiation
Lead sponsor: SeeCure LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Cancer Survivor
Interventions: educational intervention, counseling intervention, standard follow-up care, quality-of-life assessment, questionnaire administration; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 2
States / cities: Duarte, California • Lancaster, California

Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose); Biological · Drug
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Nashville, Tennessee

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer, Gynecologic Cancer, Stage I Gynecologic Cancer, Stage II Gynecologic Cancer, Stage III Gynecologic Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions: Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Risk Reduction, Breast Cancer
Interventions: Bazedoxifene and Conjugated Estrogens; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years to 64 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Duarte, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: Breast Cancer, Lymphoma
Interventions: PARASYM neuromodulation device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Tulsa, Oklahoma

Conditions: Breast Cancer
Interventions: Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 35
States / cities: Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more

Conditions: Advanced or Metastatic Breast Cancer
Interventions: Ibrance; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion
Interventions: Behavioral, Psychological or Informational Intervention, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years to 70 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy, Dense Breasts
Interventions: Molecular Breast Imaging, MBI-guided biopsy; Device
Lead sponsor: Smart Breast Corp.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer Screening, Oncology, Preventative Medicine, Mammography
Interventions: Breast Cancer Screening Decision Support Tool, National Cancer Institute Breast Cancer Screening PDQ; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 49 Years · Female only
Enrollment: 1,277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Breast Cancer
Interventions: EZN-2208; Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 36
States / cities: Sedona, Arizona • Tucson, Arizona • Murrieta, California + 30 more

Conditions: Breast Cancer, Bone Diseases
Interventions: Vitamin D; Drug
Lead sponsor: Mark Pegram; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: Panobinostat, Trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Norwalk, Connecticut + 4 more

Conditions: Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer
Interventions: Questionnaire, Patient Navigator (PN); Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 2,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: GammaPod Radiation; Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 45 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more

Conditions: Breast Cancer
Interventions: sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab, Endocrine therapy; Drug · Other · Biological
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer
Interventions: Dovitinib, Aromatase Inhibitors; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Interventions: Bemcentinib; pembrolizumab; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Duarte, California • San Diego, California • Kansas City, Missouri + 2 more

Conditions: HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: T-DM1, Pertuzumab, Excision of tumor/mastectomy; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Indocyanine green (ICG); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Metastatic ER+ Breast Cancer
Interventions: TTC-352; Drug
Lead sponsor: TTC Oncology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Scottsdale, Arizona • Saint Paul, Minnesota • Sioux Falls, South Dakota + 1 more

Conditions: Breast Cancer
Interventions: Nanomechanical Phenotype Test; Diagnostic Test
Lead sponsor: ARTIDIS AG; Industry
Eligibility: 18 Years and older
Enrollment: 2,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Seattle, Washington

Search by objective public record fields.

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

Acupuncture Pilot Study for Cancer-related Cognitive Function

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Molecular Breast Imaging (MBI)-Guided Biopsy

Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

GammaPod Dose Escalation Radiation for Early Stage Breast Cancer

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Fluorescent Dyes for Lymph Node Mapping

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions